A significantly higher percentage of women who received Livensa reported a benefit in the three endpoints, that they considered clinically meaningful compared to women who received placebo.
Un porcentaje significativamente mayor de mujeres tratadas con Livensa mostró un beneficio en las tres variables, que se consideró clínicamente significativo, frente a las mujeres que recibieron placebo.